What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.”In the company’s words, NCT06742138 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (2 trials), Relapsed or Refractory Multiple Myeloma, Malignant Plasma Cell Neoplasms
- Main trialPhase 3
- “This is a randomized, double-blind, multicenter trial,parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants with relapsed or refractory Multiple Myeloma.”In the company’s words, NCT06742138 on ClinicalTrials.gov
- Copy of
- Darzalex Faspro (Janssen Biotech), Darzalex (Janssen Biotech)Tested side by side with the original in NCT06371534, NCT06742138, NCT07400744
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up3
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2027 | To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma | |
| Phase 2Recruiting | Nov 2027 | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | |
| Phase 2Not yet recruiting | Jun 2028 | QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms | |
| Phase 1Not yet recruiting | Sep 2026 | A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects | |
| Phase 1Unknown | Apr 2025 | A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026